Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Rilvegostomig
AstraZeneca
Non-small Cell Lung Cancer
1 trial -
Rilvegostomig, DS-8201a, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CARBOPLATIN, DOCETAXEL, PACLITAXEL
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE
AstraZeneca AB
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)
1 trial -
Rina-S
Genmab A/S
Ovarian Cancer
1 trial -
Robotic Gastrectomy
The First People's Hospital of Lianyungang
Gastric Cancer (GC)
1 trial -
Roux-en-Y anastomosis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE
Hoffmann-La Roche
This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
1 trial -
Rucaparib
pharmaand GmbH
Ovarian Cancer
1 trial -
SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND
Arcus Biosciences
Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)
1 trial -
SBRT
United Therapeutics Europe Ltd
Prostate Cancer
3 trials -
SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets
Karyopharm Therapeutics Inc
endometrial cancer
1 trial -
SELPERCATINIB, CARBOPLATIN , SELPERCATINIB, PEMBROLIZUMAB, CISPLATIN , PEMETREXED
Eli Lilly Co.
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
1 trial -
SGM-101
BRIGHT MINDS BIOSCIENCES INC.
Rectal Cancer
1 trial -
SHR-A2009 ; Aumolertinib
Suzhou Ribo Life Science Co.
Non-small Cell Lung Cancer
1 trial -
SODIUM CHLORIDE, MYCOPHENOLATE MOFETIL, GLUCOSE, Oleclumab, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion., Monalizumab, IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB
AstraZeneca AB
Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)
1 trial -
SODIUM CHLORIDE, ROPIVACAINE
Pari Pharma GmbH
Cancer surgery
1 trial -
SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL
Amgen
Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation
1 trial -
SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets
Amgen
Colorectal Cancer (CRC)
1 trial -
SSGJ-707
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Advanced Non-Small Cell Lung Cancer
1 trial -
SV-BR-1-GM
BriaCell Therapeutics
Breast Cancer
2 trials -
SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
Sacituzumab Govitecan-hziy
Gilead Sciences Ireland UC
Triple Negative Breast Cancer
1 trial -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
1 trial -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer (NSCLC)
2 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources